Chronos Archive seal

Review checklist: Elvis Presley (HR-ML003)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the DSM-5-TR criteria counts (tolerance and withdrawal counted because use was not as prescribed), the MME totals, the one-week delay before buprenorphine at his choice with naloxone and seven-day supplies in between, the in-office induction, buprenorphine with a benzodiazepine, the alprazolam to diazepam conversion and the taper pace, amlodipine with valsartan as a single pill for stage 2 hypertension, tirzepatide for obesity with obstructive sleep apnea while on buprenorphine, in-laboratory polysomnography on opioids, stopping phentermine for glaucoma and blood pressure, and acute back pain treated by splitting the buprenorphine dose with naproxen.
provenance reviewnot_startedSources: The New York Times obituary (1977), Graceland's official timeline, four UPI wire reports of the 1981 trial, the 1977 Rolling Stone report, a HISTORY article (2026), and the PubMed abstract of Zegers et al. (2025). The Commercial Appeal could not be reached and the biographies were not read. The cause of death is graded R and disputed; the steroid explanation of his glaucoma is R, probable; the megacolon account is R, possible.
safe messaging reviewnot_startedDrug and mental-health claims are marked sensitive; the 1973 hospital stay and the trial testimony are recorded without detail beyond the reports; his death is recorded in one plain sentence and its disputed cause separately; person-first language; weight is described without stigma; the safety assessment gives the 988 Suicide & Crisis Lifeline and addresses means safety, including firearms. His physician appears only in documented history, with no modern decision or statement attributed to him; no living person is named, and nothing is attributed to his former wife or his daughter.

Judgment calls (dossier editorial resolutions)

  1. Sources. The case relies on The New York Times obituary of August 17, 1977 (read in its On This Day archive), Graceland's official timeline, four UPI wire reports of the 1981 trial, the 1977 Rolling Stone report, a 2026 HISTORY article, and the PubMed abstract of Zegers et al. (2025). The Memphis Commercial Appeal could not be reached by the search and fetch tools, and Peter Guralnick's biographies were not read, so neither is cited; the 1977 Rolling Stone report quotes the Commercial Appeal once, but that quotation is not used. The 1980 action of the Tennessee medical board against his physician and the 1979 ABC 20/20 broadcast were found only in secondary sources and are not claims, apart from the UPI mention of the broadcast's conclusion, which is also not used.
  2. Recent-death rule. He died in 1977, so the rule does not apply. Drug and mental-health claims are nonetheless marked sensitive, and the modern episode is synthetic throughout.
  3. Index age and dates. The index visit on July 10, 2026 maps to July 10, 1974, when he was 39: nine months after the October 1973 hospital stay in which, by later testimony, he was withdrawn from narcotic drugs, and during the few weeks off at Graceland that Graceland's timeline places from early July 1974. The synthetic date of birth is January 8, 1987 (shift 52 years). The visits on July 17, August 7 and August 14 map to the weeks off before the Las Vegas engagement of August 19 to September 2, 1974; September 9 and September 23 to the gap between that engagement and the tour of September 27 to October 14; and October 28 to the weeks after the tour. The timeline does not say where he was in each gap; no visit falls on a documented engagement. Past medical history includes only events up to October 1973; the 1975 hospital stays, the prescribing totals, the death and the trial are linked to later timeline events and are left out of the intake documents.
  4. Presenting problem. Fatigue, weight gain, constipation, daytime sleepiness and high blood pressure (R53.83) is the intake problem; it ends at the one-week visit, when the consultation, the polysomnogram and the home readings give the diagnoses of opioid use disorder (F11.20), benzodiazepine use disorder (F13.20), stage 2 hypertension (I10), obstructive sleep apnea (G47.33) and opioid-induced constipation (K59.03), all recorded on that date. Obesity and glaucoma were evident at intake and are recorded then. Intake documents name no diagnosis made later and no later treatment choice.
  5. Difference from the panel's existing record of substance use disorders from prescribed drugs. That record teaches barbiturate and stimulant use disorders from drugs given to a minor, a hospital change to phenobarbital, depression care and CBT for insomnia, with naloxone not indicated. This record teaches a polypharmacy reconciliation across five prescribers, opioid use disorder treated with buprenorphine, two benzodiazepines combined and tapered alongside buprenorphine, naloxone from the first visit, and the cardiometabolic, sleep, bowel and eye consequences of the drugs, with care around touring. The appetite suppressant is stopped as a contraindicated drug, with no stimulant use disorder diagnosed.
  6. Drugs in the modern episode. The documented record names stimulants, sedatives and painkillers in large amounts from several sources. The synthetic drugs are present-day equivalents chosen for teaching (hydromorphone, oxycodone with acetaminophen, diazepam, alprazolam and phentermine); they are not claims about the drugs he took. The roster's “10,000+ doses in the final year” is not used; the case gives the 19,000 doses over about 30 months and the 1,679 pills in 205 days that UPI reported from the trial.
  7. Cause of death (CLM-0013, R, disputed). The medical examiner gave cardiac arrhythmia and later heart disease; trial testimony reported 14 drugs in tissue samples; later accounts emphasize multiple drugs, heart disease, or straining with an enlarged colon. The case records the conflict and assumes none of these. The megacolon account comes second-hand through a biographer quoted in a 2026 article and is R, possible (CLM-0014); the 1977 report of “a blockage of the colon” is D.
  8. Liver. The only source for liver disease is an unnamed hospital employee quoted by Rolling Stone in 1977 (CLM-0005, D, probable). The synthetic episode records mildly raised liver tests that normalize with weight loss and stopping the acetaminophen-containing opioid; no liver diagnosis is coded.
  9. Glaucoma (CLM-0007, D; CLM-0008, R, probable). The 1971 acute angle-closure episode and his ophthalmologist's care are from the Zegers abstract; the steroid explanation is that review's interpretation. The modern diagnosis, glaucoma secondary to drugs (H40.63X1), is synthetic. His ophthalmologist is not named. The modern teaching point is that phentermine, decongestants and anticholinergic sleep aids are avoided in glaucoma, and steroids are used only when essential.
  10. Real people. His physician, George Nichopoulos (who died in 2016), appears only in documented trial history; no modern decision, statement or health fact is attributed to him. The medical examiner and the expert witness are not named. No living person is named. His former wife and his daughter (who died in 2023) are not named and nothing is attributed to either; the social history mentions no family member. Friends who carry naloxone, the advance care planning agent and the household are unnamed and synthetic.
  11. Firearms. The safety assessment records synthetic firearms at home, stored locked and unloaded during the medicine changes. This is a means-safety teaching point and is not linked to any historical claim.
  12. DSM-5-TR counts. Tolerance and withdrawal are counted for both disorders because the drugs were not taken as prescribed (more than prescribed, from several prescribers); the opioid use disorder is severe (seven criteria) and the benzodiazepine use disorder moderate (five). ICD-10-CM codes both as dependence, uncomplicated.
  13. Clinical judgment calls. (1) Buprenorphine was not started at intake, by his choice to see the specialist first; the week in between was covered by naloxone, a single prescriber, seven-day supplies at the verified doses and a locked box. (2) A standard in-office start at COWS 12, rather than a low-dose start. (3) Alprazolam was combined into diazepam at 40 mg a day, a cautious equivalent, and held for three weeks before tapering; steps of about 6 to 11% every five to seven weeks, held during the engagement. (4) Buprenorphine was not withheld because of the benzodiazepine. (5) Amlodipine with valsartan as one pill for stage 2 hypertension more than 10 mmHg above the diastolic target; a thiazide was avoided because of his angle-closure history. (6) Tirzepatide rather than semaglutide because it is approved for obstructive sleep apnea with obesity, started only after buprenorphine was stable and the bowels regular. (7) In-laboratory polysomnography because chronic opioids make home testing unreliable. (8) Phentermine and the diphenhydramine sleep aid were stopped at intake. (9) Acute back pain was managed by splitting buprenorphine, with naproxen and no muscle relaxant or full-agonist opioid. (10) MME uses the CDC 2022 conversion factors (hydromorphone 5, oxycodone 1.5).
  14. Instruments. STOP-Bang, the Epworth Sleepiness Scale and COWS have no LOINC code on the terminology server and are recorded as narrative; the polysomnogram and the point-of-care urine drug tests are recorded as a procedure and in narrative. PHQ-9, GAD-7, DAST-10 and AUDIT-C use LOINC survey codes.
  15. Code verification. The public terminology server returned errors for a time during the build; ICD-10-CM codes were checked first against the NLM Clinical Tables service and then confirmed on the terminology server; LOINC, SNOMED CT, CVX and RxNorm codes were checked on the terminology server and RxNav.
  16. Synthetic clinical picture. Everything in the modern episode is synthetic: the five prescribers, the doses, the urine tests, the diagnoses, the sleep study, every laboratory value and score, the vital signs, the medicines, the back strain and the outcomes. Height (183 cm, about six feet) follows the 1977 obituary; the weights are synthetic.
  17. Preventive visit. A periodic adult preventive visit at 39 (CPT 99395 with 99497 in plain text). Lipids with no statin at 39; prediabetes noted from intake; obesity behavioral counseling; drug-use screening already done; one-time HIV, hepatitis C and hepatitis B screening (HIV and hepatitis C nonreactive, no hepatitis B immunity), so two HepB-CpG doses followed at the ten-week and four-month visits; Tdap; influenza and COVID-19 vaccines in the autumn; colorectal screening not yet due; advance care planning records an unnamed agent.
  18. Sick visit. An acute low back strain after karate practice, chosen because it tests the plan: acute pain on buprenorphine is treated by splitting the dose and adding non-opioid treatment, without a full-agonist opioid, a muscle relaxant that would add sedation, or imaging. Karate is a synthetic detail consistent with the Graceland note that he talked about karate on stage in August 1974; the injury is not a historical claim.
  19. Focused visits. The four chronic-care follow-ups (one week with the consultation, three weeks, ten weeks, four months) are documented as focused visits on ASAM 2020, the 2025 joint benzodiazepine guideline, CDC 2022 and the CDC monitoring-program guidance, the 2025 AHA/ACC guideline and CMID hypertension monograph, the AGA obesity guideline and SURMOUNT-OSA, the AASM guidelines, the AGA constipation guidelines, the AAO pattern and CMID glaucoma monograph, and the CMID depression monograph with the VA/DoD suicide-risk guideline. Two deviations are recorded instead of invented results: (1) the urine drug test due at three weeks was not collected because he left for a rehearsal; no harm was evident (monitoring program clean), and it was collected at the start of the ten-week visit and was as expected; (2) the second weekly video visit during the Las Vegas engagement was missed; a nurse called the next day and found him well, and the corrective action, a fixed weekly time with a same-day backup, held through the tour. Synthetic findings introduced: mild nausea after tirzepatide doses and the back strain.
  20. Consultation. The addiction medicine referral and the consultation by Rosalind Eberhardt-Mensah, MD (a fictional consultant), on the day of the one-week visit, are S. The consultant answers the five referral questions in line with what the record shows afterwards: severe opioid use disorder and moderate benzodiazepine use disorder, an in-office standard buprenorphine start at 16 mg, alprazolam combined into diazepam 40 mg with a slow taper after buprenorphine was stable, naloxone, the monitoring program, urine testing and weekly contact (the missed test is a recorded deviation), touring arrangements, and the acute-pain plan used at the sick visit.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-08-07
Progress note 03 (C-CDA)
Urine drug test, including buprenorphine metabolite and fentanylAt the start of treatment, then about monthly while doses are changingNot collected: he left for a rehearsal before giving a sample. No harm is evident: the monitoring program shows only this clinic's prescriptions and he reports no other use. Corrective action: sample to be collected at the start of the next visit
2026-09-23
Progress note 06 (C-CDA)
Weekly video visits while awayWeekly during engagements and toursThe second weekly video visit in Las Vegas was missed when a rehearsal ran late; a nurse reached him by phone the next day and found him well. No harm resulted. Corrective action: a fixed weekly time on tour with a backup slot the same day

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-08-14
Progress note 04 (C-CDA)
PreventionHIV screeningOrderedOnce for all adults; drawn today with his agreement
2026-08-14
Progress note 04 (C-CDA)
PreventionHepatitis C screeningOrderedOnce for all adults; drawn today
2026-08-14
Progress note 04 (C-CDA)
PreventionHepatitis B screeningOrderedTriple panel once for all adults; drawn today

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0008A 2025 ophthalmology review interprets his glaucoma as steroid-induced, from lifelong use of steroids both prescribed and self-administered, with secondary angle closure most likely due to anterior uveitis.probable
CLM-0013The cause of his death is disputed. The medical examiner gave cardiac arrhythmia, citing a history of mild hypertension and evidence of coronary artery disease, and later ruled it heart disease; the autopsy report was never released. Trial testimony said that 14 drugs, including codeine at ten times the maximum accepted level, were found in tissue samples, and later accounts attribute the death to multiple prescription drugs, to heart disease, or to straining with a severely enlarged colon.disputed
CLM-0014His physician later said that he had a severe form of megacolon, his colon about twice its normal diameter and impacted with stool at his death.possible

Sensitive claims

ClaimGradeStatement
CLM-0003DFrom October 15 to November 1, 1973, he was treated at Baptist Memorial Hospital in Memphis under an assumed name; at the 1981 trial of his physician, an internal medicine specialist who reviewed the records testified that the consulting physicians were "withdrawing him from narcotic drugs."
CLM-0004DHe was treated at Baptist Hospital again from January 28 to February 13, 1975, when the admission note recorded abdominal problems and swelling of the face, hands and legs, and from August 21 to September 25, 1975, for shortness of breath and swelling. In 1977 the medical examiner said that the drugs he found were those prescribed for hypertension and a blockage of the colon, for which Presley had been hospitalized twice in 1975.
CLM-0005DIn 1977 an unnamed Baptist Hospital employee told Rolling Stone that he had been treated there for "hypertension, enlarged colon, gastroenteritis, stomach inflammation," had "a severe liver condition," had received cortisone, and weighed at least 230 pounds; the hospital's doctors discounted a suggestion of lupus.
CLM-0008RA 2025 ophthalmology review interprets his glaucoma as steroid-induced, from lifelong use of steroids both prescribed and self-administered, with secondary angle closure most likely due to anterior uveitis.
CLM-0009DAt the 1981 trial of his physician, George Nichopoulos, prosecutors showed that the physician had prescribed about 19,000 doses of stimulants, sedatives and painkillers for him in the last 30 months of his life, including 1,679 addictive pills in 205 days between the two 1975 hospital stays; the defense argued that he obtained drugs from many other sources, including amphetamines mailed from the West Coast, and a detective testified to collecting prescriptions from 140 Memphis pharmacies.
CLM-0010DTestimony at the trial described him as addicted to prescribed stimulants, sedatives and painkillers; the internal medicine specialist testified, "Absolutely. He was addicted." On November 4, 1981, the jury acquitted the physician of overprescribing, citing his efforts to substitute placebos and intercept drugs sent from elsewhere; the physician then said that drugs "may have played a part" in the death.
CLM-0011DIt was believed that he neither smoked nor drank alcohol.
CLM-0013RThe cause of his death is disputed. The medical examiner gave cardiac arrhythmia, citing a history of mild hypertension and evidence of coronary artery disease, and later ruled it heart disease; the autopsy report was never released. Trial testimony said that 14 drugs, including codeine at ten times the maximum accepted level, were found in tissue samples, and later accounts attribute the death to multiple prescription drugs, to heart disease, or to straining with a severely enlarged colon.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-07-10Glucose104 mg/dL (high)High
2026-07-10Hemoglobin A1c5.8% (high)High
2026-07-10ALT72 U/L (high)High
2026-07-10AST52 U/L (high)High
2026-07-10GGT78 U/L (high)High
2026-08-14Total cholesterol214 mg/dL (high)High
2026-08-14HDL cholesterol38 mg/dL (low)Low
2026-08-14LDL cholesterol (calculated)140 mg/dL (high)High
2026-08-14Triglycerides180 mg/dL (high)High